Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting
Authors:
- Auro del GiglioAGAuro del Giglio
- Heloisa P. SoaresHSHeloisa P. Soares
- Carla CaparrozCCCarla Caparroz
- Paulo C. CastroPCPaulo C. Castro
Abstract
The introduction of serotonin antagonists as antiemetics for prophylaxis of chemotherapy-induced nausea and vomiting represented a major step toward better patient tolerance and adherence to this type of treatment. Several published trials compared different serotonin antagonists without demonstrating clear superiority of any one of them. Because most of these trials compared ondansetron with granisetron, the authors conducted a meta-analysis to determine if the current data available show any therapeutic difference between them. MEDLINE and CANCERLIT databases were searched from 1990 to May 1999, and pertinent article references also were surveyed, without restriction to English language. The authors included all randomized controlled trials (RCTs) that had more than 25 patients per arm and compared ondansetron to granisetron for prophylaxis of acute (A) (< 24 hours) and delayed (D) (> 24 hours) nausea (N) and vomiting (V) induced by highly (H) or moderately (M) emetogenic chemotherapy. Only the first chemotherapy cycle was considered for studies that involved a crossover design. Fourteen studies with 6467 evaluable patients among the 21 studies retrieved were selected for this meta-analysis. In none of the eight scenarios studied (AHV, AHN, AMV, AMN, DHV, DHN, DMV, and DMN) could the authors detect any significant differences in the antiemetic efficacy of any of these medications. The authors conclude that both granisetron and ondansetron have similar antiemetic efficacy for prophylaxis of chemotherapy-induced nausea and vomiting. Because the number of comparative studies that addressed the delayed nausea and vomiting scenarios is low, further RCTs are still needed to confirm these results. Cancer 2000;89:2301–8. © 2000 American Cancer Society.Keywords
This publication has 21 references indexed in Scilit:
- Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice GuidelinesJournal of Clinical Oncology, 1999
- Serotonin Receptor Antagonists in Prophylaxis of Acute and Delayed Emesis Induced by Moderately Emetogenic, Single-Day ChemotherapyAmerican Journal of Clinical Oncology, 1999
- Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: A quantitative systematic reviewEuropean Journal of Cancer, 1998
- Consensus proposal for 5HT 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapySupportive Care in Cancer, 1998
- Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.Journal of Clinical Oncology, 1998
- An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomitingEuropean Journal of Cancer, 1997
- Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trialCancer, 1996
- Prevention of Delayed Emesis by a Single Intravenous Bolus Dose of 5-HT3-Receptor- Antagonist in Moderately Emetogenic ChemotherapyJournal of Chemotherapy, 1996
- Is Navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis?Anti-Cancer Drugs, 1995
- 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised studyEuropean Journal of Cancer, 1993